Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Zappasodi

Showing results (21-30 of 67) with videos related to

Pageof 7
Sort By:
Science Advances|February 25, 2022
Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanismChanghao He, Rachana R Maniyar, Yahel Avraham, et al.
Cancer Immunology Research|May 6, 2014
Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlatesFrancesca Avogadri, Roberta Zappasodi, Arvin Yang, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitorsHarriet Kluger, J Carl Barrett, Justin F Gainor, et al.
Archives of Biochemistry and Biophysics|July 18, 2020
Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolismLeïla Sarah Sellam, Roberta Zappasodi, Fayçal Chettibi, et al.
Cancer Research|September 24, 2010
Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanomaAndrea Anichini, Alessandra Molla, Claudia Vegetti, et al.
Cancer Research|October 2, 2010
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic deathRoberta Zappasodi, Serenella M Pupa, Gaia C Ghedini, et al.
Hematological Oncology|July 22, 2017
Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstatAnna Rossini, Franco Zunino, Giusi Ruggiero, et al.
Advances in Cancer Research|July 29, 2015
The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome MalignancyDanny N Khalil, Sadna Budhu, Billel Gasmi, et al.
The Journal of Clinical Investigation|September 3, 2024
Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor modelsSvena Verma, Sadna Budhu, Inna Serganova, et al.
Blood|September 24, 2008
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot studyMassimo Di Nicola, Roberta Zappasodi, Carmelo Carlo-Stella, et al.
Pageof 7

Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
Science Advances|February 25, 2022
Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanismChanghao He, Rachana R Maniyar, Yahel Avraham, et al.
Cancer Immunology Research|May 6, 2014
Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlatesFrancesca Avogadri, Roberta Zappasodi, Arvin Yang, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitorsHarriet Kluger, J Carl Barrett, Justin F Gainor, et al.
Archives of Biochemistry and Biophysics|July 18, 2020
Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolismLeïla Sarah Sellam, Roberta Zappasodi, Fayçal Chettibi, et al.
Cancer Research|September 24, 2010
Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanomaAndrea Anichini, Alessandra Molla, Claudia Vegetti, et al.
Cancer Research|October 2, 2010
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic deathRoberta Zappasodi, Serenella M Pupa, Gaia C Ghedini, et al.
Hematological Oncology|July 22, 2017
Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstatAnna Rossini, Franco Zunino, Giusi Ruggiero, et al.
Advances in Cancer Research|July 29, 2015
The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome MalignancyDanny N Khalil, Sadna Budhu, Billel Gasmi, et al.
The Journal of Clinical Investigation|September 3, 2024
Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor modelsSvena Verma, Sadna Budhu, Inna Serganova, et al.
Blood|September 24, 2008
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot studyMassimo Di Nicola, Roberta Zappasodi, Carmelo Carlo-Stella, et al.
Pageof 7